Use of oral endothelin-receptor antagonist bosentan in the treatment of portopulmonary hypertension [2]

Transplantation

Volumn 77, Issue 11, 2004, Pages 1775-1776

  Halank, Michael ^a   Miehlke, Stephan ^a   Hoeffken, Gert ^a   Schmeisser, Alexander ^a   Schulze, Matthias ^a   Strasser, Ruth H ^a  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BOSENTAN; ENDOTHELIN RECEPTOR ANTAGONIST;

AGED; BICYCLE ERGOMETRY; CASE REPORT; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; ESOPHAGUS VARICES; HEART CATHETERIZATION; HEART INDEX; HEART RIGHT VENTRICLE PRESSURE; HEPATOPULMONARY SYNDROME; HUMAN; HYPERTENSION; LETTER; LIVER CIRRHOSIS; LIVER FUNCTION; LIVER TOXICITY; LIVER TRANSPLANTATION; LUNG ARTERIOVENOUS SHUNT; LUNG ARTERY PRESSURE; LUNG TRANSPLANTATION; MALE; OXYGEN CONSUMPTION; PORTAL HYPERTENSION; PORTAL VEIN; PORTAL VEIN BLOOD FLOW; PORTOPULMONARY HYPERTENSION; PRIORITY JOURNAL; PULMONARY HYPERTENSION;

ADMINISTRATION, ORAL; AGED; ANTIHYPERTENSIVE AGENTS; HUMANS; HYPERTENSION, PORTAL; HYPERTENSION, PULMONARY; MALE; RECEPTORS, ENDOTHELIN; SULFONAMIDES;

EID: 2942639967     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.TP.0000122420.86904.89     Document Type: Letter

References (4)

1. Channick RN, Simonneau G, Sitbon O, et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with primary pulmonary hypertension: a randomised placebo-controlled study. Lancet 2001; 358: 1119.
2. Rubin LJ, Badesch DB, Barst R, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002; 346: 896.
3. Sogni P, Moreau R, Gomola A, et al. Beneficial hemodynamic effects of bosentan, a mixed ET(A) and ET(B) receptor antagonist, in portal hypertensive rats. Hepatology 1998; 28: 655.
4. Reichen J, Gerbes AL, Steiner MJ, et al. The effect of endothelin and its antagonist bosentan on hemodynamics and microvascular exchange in cirrhotic rat liver. J Hepatol 1998; 28: 1020.